43 reports of this reaction
2.0% of all OMEPRAZOLE, SODIUM BICARBONATE reports
#8 most reported adverse reaction
TUBULOINTERSTITIAL NEPHRITIS is the #8 most commonly reported adverse reaction for OMEPRAZOLE, SODIUM BICARBONATE, manufactured by CVS Pharmacy. There are 43 FDA adverse event reports linking OMEPRAZOLE, SODIUM BICARBONATE to TUBULOINTERSTITIAL NEPHRITIS. This represents approximately 2.0% of all 2,134 adverse event reports for this drug.
Patients taking OMEPRAZOLE, SODIUM BICARBONATE who experience tubulointerstitial nephritis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
TUBULOINTERSTITIAL NEPHRITIS is a less commonly reported adverse event for OMEPRAZOLE, SODIUM BICARBONATE, but still significant enough to appear in the safety profile.
In addition to tubulointerstitial nephritis, the following adverse reactions have been reported for OMEPRAZOLE, SODIUM BICARBONATE:
The following drugs have also been linked to tubulointerstitial nephritis in FDA adverse event reports:
TUBULOINTERSTITIAL NEPHRITIS has been reported as an adverse event in 43 FDA reports for OMEPRAZOLE, SODIUM BICARBONATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
TUBULOINTERSTITIAL NEPHRITIS accounts for approximately 2.0% of all adverse event reports for OMEPRAZOLE, SODIUM BICARBONATE, making it a notable side effect.
If you experience tubulointerstitial nephritis while taking OMEPRAZOLE, SODIUM BICARBONATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.